Hansa Biopharma AB (publ)
HNSBF
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.59B
Close$
Share Statistics
| Market cap | $3.59 Billion |
|---|---|
| Enterprise Value | $4.07 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.55 |
| Beta | 1.58 |
| Outstanding Shares | 101,763,222 |
Return
| Return on Equity | 147.67% |
|---|---|
| Return on Assets | -71.74% |
| Return on Invested Capital | -112.13% |
Valuation & Multiples
| P/E Ratio | -4.58 |
|---|---|
| PEG | -10.02 |
| Price to Sales | 3.29 |
| Price to Book Ratio | -0.55 |
| Enterprise Value to Revenue | 21.52 |
| Enterprise Value to EBIT | -7.03 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | -1.99 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 22, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$5.17 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$0.61
Average shareholder expectationRevenue Estimate
$32.20 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hansa Biopharma AB (publ)
131 employees
CEO: Renée Julie Elisabet Aguiar-Lucander Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare...